Bridge chooses Catalent for opioid addiction treatment manufacture

By Vassia Barba

- Last updated on GMT


Related tags Catalent Catalent pharma solutions Drug delivery Clinical supply

Catalent completes clinical production of opioid addiction therapeutic developed by Bridge using Zydis technology and gets exclusive license ahead of regulatory filing.

Bridge Therapeutics has developed BT-219 (buprenorphine and naloxone), an investigational treatment for opioid addiction, and formulated the candidate using Catalent’s orally disintegrating tablet (ODT) technology, known as Zydis​. 

The latter company announced that it has completed the clinical production of the drug, and signed an exclusive licensing agreement with Bridge on Zydis for the future manufacturing needs of the candidate.

In November​, Bridge announced plans to submit a new drug application to the US Food and Drug Administration (FDA) ‘in the coming months’, after having received positive feedback during a pre-investigational new drug meeting with the regulatory agency.

BT-219 contains the same active ingredients as Suboxone, which is marketed by Indivior, only it would be administered with the advantages of Zydis ODT technology.

Zydis technology enables the production of a freeze-dried, sublingual tablet which disperses almost instantly in the mouth without water, offering improved patient compliance, adherence and convenience, due to taste masking and increased drug load potential, according to Catalent.

Moreover, Greg Sullivan, chief medical officer of Bridge, commented that utilizing the Zydis formulation technology “lessens the chance of an institutionalized patient being able to divert the medication for untoward purposes.”

The companies announced that Bridge’s exclusive license of the Zydis delivery technology will initially apply to the US, with the potential to expand to other nations.

Catalent’s Zydis development and manufacturing operations take place at the company’s facilities in Swindon, UK, with over one billion tablets being produced annually. According to Jonathan Arnold, president of Catalent’s Oral and Specialty Delivery business unit, over 36 products have been launched using Zydis technology in over 60 countries, to date.

According to Bridge, buprenorphine is considered safer and less addictive than methadone as a treatment for opioid addiction, a crisis​ that has placed the US in national emergency since 2017, with an average of 130 Americans losing their lives every day​.

The FDA has been supporting the development of opioid reversal drugs, as well as the approval of generics​ to make the treatments more accessible.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more